Lien Vo

Lien Vo

Auto-generated profile, based on publicly available information

Lien Vo

Bristol Myers Squibb, Lawrenceville, NJ 08648, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Future Oncology
Verified
Journal Article
Open access
ENEric Nadler
Eric Nadler
AVAnupama Vasudevan
Anupama Vasudevan
CWChuck Wentworth
Chuck Wentworth
NRNicholas Robert
Nicholas Robert
JPJohn R Penrod
John R Penrod
LVLien Vo
Lien Vo
Aim: Pathologic response has been shown to be a promising surrogate for survival in non-small-cell lung cancer (NSCLC). We examined the real-world relationship between these end points in patients ... Plain language summary – A faster way to see if new cancer drugs work Many patients with early-stage lung cancer have their cancer come back in 2–5 years after treatment, and when it returns it is ... Tweetable abstract In patients with resectable stage IB-IIIA non-small-cell lung cancer receiving neoadjuvant chemotherapy/chemoradiotherapy at community oncology practices, complete pathologic res...

8 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NGNicolas Girard
Nicolas Girard
MBMariam Besada
Mariam Besada
BRBasia Rogula
Basia Rogula
SLStefano Lucherini
Stefano Lucherini
LVLien Vo
Lien Vo
JSJonathan D. Spicer
Jonathan D. Spicer
Background: This study aimed to estimate the relative efficacy of neoadjuvant nivolumab in combination with chemotherapy (neoNIVO + CT) compared to relevant treatments amongst resectable non-metastatic non-small-cell lung cancer (rNSCLC) patients. Methods: Treatment comparisons were based on a network meta-analysis (NMA) using randomized clinical trial data identified via systematic literature review (SLR). The outcomes of interest were event-free survival (EFS) and pathological complete response (pCR). NeoNIVO + CT was compared to neoadjuvant chemotherapy (neoCT), neoadjuvant chemoradiotherapy (neoCRT), adjuvant chemotherapy (adjCT), and surgery alone (S). Due to the potential for effect modification by stage, all-stage and stage-specific networks were considered. Fixed-effect (FE) and random-effects Bayesian NMA models were run (EFS = hazard ratios [HR]; pCR = odds ratios [OR]; 95% credible intervals [CrI]). Results: Sixty-one RCTs were identified (base case = 9 RCTs [n = 1978 patients]). In the all-stages FE model, neoNIVO + CT had statistically significant EFS improvements relative to neoCT (HR = 0.68 [95% CrI: 0.49, 0.94]), S (0.59 [0.42, 0.82]), adjCT (0.66 [0.45, 0.96]), but not relative to neoCRT (HR = 0.77 [0.52, 1.16]). NeoNIVO + CT (5 RCTs) had statistically significant higher odds of pCR relative to neoCT (OR = 12.53 [5.60, 33.82]) and neoCRT (7.15 [2.31, 24.34]). Stage-specific model findings were consistent. CONCLUSIONS: This NMA signals improved EFS and/or pCR of neoNIVO + CT relative to comparators among patients with rNSCLC.